Estriol 0.01% vaginal cream
Requires a prescription from a doctor or prescriber
A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Estriol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Estriol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
8 branded products available
Part of the Gynest brand family (generic: Estriol)
MHRA licensed products
View all licensed products for Estriol on the MHRA register
Gynest 0.01% cream
Estriol 0.01% vaginal cream
Estriol 0.01% vaginal cream
Estriol 0.01% vaginal cream
WHO defined daily dose (DDD)
200 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Menopause: identification and management (NG23)
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 14 · 1964–2026
Showing the 50 most relevant studies, sorted by most relevant.
V. Cruz, M. Steiner, L. Pompei, et al.
Menopause, 2017
Rhonda R. Voskuhl, He-Jing Wang, T. C. Jackson Wu, et al.
The Lancet. Neurology, 2016
Andrews RAF, Lacey A, Roach H, et al.
2025
- Menopause
- Probiotics
- Vagina
This review investigated the impact of probiotics during the menopause transition and explored their potential to enhance the effectiveness of estrogenic substances in perimenopausal or recently postmenopausal women. A thorough literature search of EMBASE, MEDLINE, Cochrane Library, Scopus, and Web of Science was conducted, identifying 39 studies involving 3187 women. Quality assessments were conducted using the relevant Cochrane Risk of Bias tools. The results demonstrated that probiotics had positive effects on menopausal symptoms, urogenital health, bone health, and the efficacy and safety of estriol and isoflavones. Meta analysis of 7 studies comparing probiotics versus placebo demonstrated large effects of probiotics on menopausal symptoms (total score) [standardized mean difference (SMD) = 0.82, 95 % CI -0.52 to -1.09], vasomotor symptoms (SMD = -0.96, 95 % CI -1.25 to -0.68), psychological symptoms (SMD = -0.51, 95 % CI -0.95 to -0.08), vaginal dryness (SMD = 0.95, 95 % CI -1.40 to -0.49), and vaginal microbiome health (Nugent score) (SMD = -0.91, 95 % CI -1.32 to -0.49). Meta-analysis results were nonsignificant for reducing somatic and sexual symptoms. Probiotics hold promise in addressing symptoms related to low estrogen levels and may enhance the effects of estriol and isoflavones, offering potential benefits as part of the management of menopausal women. It's important to note that the included studies had a high risk of bias, emphasising the need for further rigorous research in this area. Should findings continue to show promise, clinicians should consider incorporating probiotics into their strategies for managing menopausal symptoms. SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42019146270.
Abstract licence: CC BY
Ashraf M, Shoraka E, Shahabi S, et al.
2026
TopicKeratoconus (KCN) is a progressive corneal ectasia with poorly understood etiology and risk factors leading to inadequate screening methods for at-risk populations. One potentially vulnerable population includes individuals experiencing fluctuations in hypothalamic-pituitary-gonadal (HPG) axis hormones. This systematic review aims to evaluate the association between HPG-axis hormonal fluctuations and the development or progression of KCN.Clinical relevanceElucidating the relationship between HPG-axis hormone fluctuations and KCN may enhance screening strategies, facilitate early detection, and inform preventive measures in at-risk populations. Improved awareness among clinicians could lead to targeted monitoring and timely interventions.MethodsA comprehensive literature search was conducted in PubMed, Scopus, Web of Science, Embase, and Google Scholar databases up to July 2025, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if they provided clinical evidence of associations between HPG-axis hormone fluctuations and KCN onset or progression. Two reviewers independently extracted relevant data on hormone changes and KCN. Methodological quality was assessed using the Joanna Briggs Institute (JBI) appraisal tools.ResultsTwenty-six studies met inclusion criteria, comprising 16 descriptive studies and 10 case-control studies, with an aggregate of 4201 participants (∼8000 eyes). Endogenous hormonal shifts related to pregnancy and congenital hormonal abnormalities accounted for 56.2% of identified triggers (9 of 16 studies; 26 patients), while exogenous hormone exposure from hormone replacement therapy and antiandrogen treatment represented 31.2% (5 of 16 studies; 7 patients). Ten case-control studies included 3834 participants (1623 KCN patients and 2211 controls). Of these 10, 8 studies (80%) demonstrated significant alterations in sex steroid hormones (elevated dehydroepiandrosterone sulfate [DHEAS] and estradiol; decreased estrone and estriol; mixed results for testosterone) or gonadotropins (altered luteinizing hormone/follicle-stimulating hormone ratios, reduced gonadotropin-releasing hormone) in association with KCN. Methodological quality assessment indicated that 22 of the 26 studies had high reporting quality per JBI items.ConclusionThis systematic review highlights consistent associations between HPG-axis hormone fluctuations and KCN development and progression, as evidenced across observational studies. Specifically, altered levels of DHEAS, estrogens, and gonadotropins emerged as key hormones linked to KCN pathology. These findings support a systemic component in the etiology of KCN, underscoring the importance of hormonal influences in clinical management and screening, particularly during periods of significant hormonal fluctuation, such as pregnancy, congenital endocrine disorders, or hormonal therapy.Financial disclosuresProprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Abstract licence: CC BY-NC-ND
Stute, P; https://orcid.org/, Betschart, C, Betschart, C; https://orcid.org/, et al.
Taylor & Francis, 2024
de Paula SRC, Mendes MC, Okano SHP, et al.
2025
- Dyspareunia
- Estriol
- Coitus
Zunino AX, Torre PA, Cristina Aidé Viviani S, et al.
2025
- Vagina
- Estriol
- Menopause
Liu L, Li C, Liu C, et al.
2025
- Thyroiditis, Autoimmune
- Estriol
- Cosmetics
Torre PA, Fialho SCAV, do Val Guimarães ICC, et al.
2026
- Estriol
- Menopause
- Female Urogenital Diseases
Chinthakanan O, Sarit-Apirak S, Aimjiraku K, et al.
2025
- Lactobacillus
- Estriol
- Pessaries
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Estriol levels can be measured to give an indication of the general health of the fetus.
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 567 interactions
Proteins and enzymes this drug interacts with in the body
Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter.
Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP.
Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3 .
PMID:17922032
Maintains neuronal survival in response to ischemic reperfusion injury when in the presence of circulating estradiol (17-beta-estradiol/E2) (By similarity)
Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration
Proteins that transport this drug across cell membranes
PMID:19129463 PMID:7557095
Responsible for intestinal absorption of bile acids (By similarity). Transports dehydroepiandrosterone 3-sulfate (DHEAS), a major circulating steroid secreted by the adrenal cortex, as well as estrone 3-sulfate and 17beta-estradiol 17-O-(beta-D-glucuronate) .
PMID:11159893 PMID:12568656 PMID:19129463 PMID:23918469 PMID:25560245 PMID:9539145
Mediates apical uptake of all-trans-retinol (atROL) across human retinal pigment epithelium, which is essential to maintaining the integrity of the visual cycle and thus vision .
PMID:25560245
Involved in the uptake of clinically used drugs .
PMID:17301733 PMID:20686826 PMID:27777271
Capable of thyroid hormone transport (both T3 or 3,3',5'-triiodo-L-thyronine, and T4 or L-tyroxine) .
PMID:19129463 PMID:20358049
Also transports prostaglandin E2 .
PMID:19129463
Plays roles in blood-brain and -cerebrospinal fluid barrier transport of organic anions and signal mediators, and in hormone uptake by neural cells (By similarity). May also play a role in the reuptake of neuropeptides such as substance P/TAC1 and vasoactive intestinal peptide/VIP released from retinal neurons .
PMID:25132355
May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drugs methotrexate and paclitaxel .
PMID:23243220
Shows a pH-sensitive substrate specificity which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment .
PMID:19129463
Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions .
PMID:19129463
May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC G03CC06
ATC G03CA04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Estriol
Additional database identifiers
ChemSpider
5553
BindingDB
50410506
PDB
ESL
ZINC
ZINC000003815418
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3467
GenAtlas
ESR1
GeneCards
ESR1
GenBank Gene Database
X03635
GenBank Protein Database
31234
Guide to Pharmacology
620
UniProt Accession
ESR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3468
GenAtlas
ESR2
GeneCards
ESR2
GenBank Gene Database
AB006590
GenBank Protein Database
2911152
Guide to Pharmacology
621
UniProt Accession
ESR2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10839
GenAtlas
SHBG
GeneCards
SHBG
GenBank Gene Database
X16349
GenBank Protein Database
296673
UniProt Accession
SHBG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10956
GeneCards
SLCO1A2
GenBank Gene Database
U21943
GenBank Protein Database
885978
Guide to Pharmacology
1219
UniProt Accession
SO1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72